secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2024-03-22T23:59:59+00:00
Accession:  0000950170-24-035376
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences FY2023 net loss narrows to $0.1M; cash $12.0M through 2024
--------------------------------------------------------------------------------

- Year-end cash $12.0M vs $5.3M; company believes sufficient to fund operations through 2024.
- Net loss for FY2023 $0.1M (EPS -$0.53) vs $10.8M loss ($149.20 EPS) in 2022, due to $8.3M warrant liability gain.
- Q4 2023 net loss $2.2M ($8.33 EPS) vs $1.2M loss ($15.61 EPS) in Q4 2022; operating cash burn $2.0M.
- Completed $6.2M public offering; began Phase 1 study of Gemini; presented positive preclinical AKI data.
- Net cash used in operations for FY2023 was $7.3M, down from $11.2M in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017024035376/0000950170-24-035376-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017024035376/revb-20240322.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-035376

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer